ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Sunday, November 13, 2016

9:00AM-11:00AM
Abstract Number: 775
Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies
9:00AM-11:00AM
Abstract Number: 373
Evidence for TMJ Pain As a Component of a Generalized Pain Phenotype
Pain – Basic and Clinical Aspects - Poster
9:00AM-11:00AM
Abstract Number: 535
Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis
9:00AM-11:00AM
Abstract Number: 208
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Metabolic and Crystal Arthropathies - Poster I: Clinical Practice
9:00AM-11:00AM
Abstract Number: 826
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I
9:00AM-11:00AM
Abstract Number: 329
Explore the Possible Mechanisms of 1,25(OH)2D3 on the Formation of Osteoclasts in Rheumatoid Arthritis
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster
9:00AM-11:00AM
Abstract Number: 488
Exploring the Association Between Air Pollutant Exposure and Seropositivity in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis
9:00AM-11:00AM
Abstract Number: 643
Exposure-Response Analyses of Efficacy of ABT-122, a Dual-Variable Domain Immunoglobulin (DVD-Ig™) Targeting TNF-α and IL-17A, Compared with Adalimumab in Subjects with Rheumatoid Arthritis and Background MTX
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
9:00AM-11:00AM
Abstract Number: 761
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies
9:00AM-11:00AM
Abstract Number: 874
Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19)  in Giant-Cell Arteritis Lesions.  Potential Role of p40 in Promoting Th1 -Mediated Pathways
Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 278
Expression of Anti-Microbial Peptide LL-37 Correlates to the Activation of Type I Interferon Pathway in Patients with Idiopathic Inflammatory Myopathies
Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational
9:00AM-11:00AM
Abstract Number: 660
Expression of the Chemokine Receptor CXCR5 Is Decreased in the Periphery of Patients with Primary Sjogren’s Syndrome
Sjögren's Syndrome - Poster I: Translational Science
9:00AM-11:00AM
Abstract Number: 657
Expression of Type-III Interferons (IFNλs) and Their Receptor in Sjögren’s Syndrome
Sjögren's Syndrome - Poster I: Translational Science
9:00AM-11:00AM
Abstract Number: 283
Extracellular Histidyl-tRNA Synthetase in Myositis
Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational
9:00AM-11:00AM
Abstract Number: 820
EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I
  • «Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 70
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology